Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Valneva's VLA15 study continues apace
July 2019
SHARING OPTIONS:

SAINT-HERBLAIN, France—June saw biotech company Valneva SE announce that its Phase 2 study for VLA15 had moved into the main study phase, with an independent data safety monitoring board having cleared two dosage levels for clinical development. VLA15 is being evaluated as a Lyme disease vaccine, and in a Phase 1 trial, it presented with a favorable safety profile, was immunogenic in all doses and formulations tested, and triggered a strong anamnestic response after a booster vaccination administered 12 to 15 months after initial immunization. The company intends to launch another Phase 2 study to investigate an alternative immunization, with an expected initiation in Q3 2019.
 
“We are pleased that the run-in safety data confirm our hypothesis that we can proceed with higher doses than initially studied in Phase 1. Given the well-understood mode of action, high anti-OspA antibody titers are key to deliver a highly effective vaccine that will address the significant unmet medical need arising from the increasing spread of Lyme disease,” commented Dr. Wolfgang Bender, chief medical officer of Valneva.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.